Want to see DNA full AI Analyst Report?
Top Page
Ginkgo Bioworks Holdings
(NYSE:DNA)
Select Model
Select Model
Rating:55Neutral
Price Target:
$13.50
▲(79.05% Upside)
Action:Reiterated
Date:10/08/26
Overall score reflects weak fundamentals as the main constraint (shrinking revenue, large operating losses, and ongoing cash burn), partially offset by improving cost discipline and a solid liquidity position reiterated on the earnings call. Technical indicators are supportive with price above major moving averages and positive momentum, but valuation remains unattractive due to continued losses and no dividend support.
Positive Factors
High Gross Margin
The very high gross margin indicates that delivered services can generate attractive contribution economics before operating overhead. If Ginkgo converts more programs into recurring work and scales utilization, this margin profile could support stronger operating leverage over the next several quarters.
Negative Factors
Severe Revenue Contraction
The sharp and sustained decline in reported revenue shows that customer-program volume, commercialization timing, or both remain insufficient to support the current business base. Continued contraction would weaken operating leverage, reduce funding capacity, and make durable profitability harder to reach.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
The very high gross margin indicates that delivered services can generate attractive contribution economics before operating overhead. If Ginkgo converts more programs into recurring work and scales utilization, this margin profile could support stronger operating leverage over the next several quarters.
Read all positive factors
Ginkgo Bioworks Holdings Key Performance Indicators (KPIs)
Any
Operating Income by Segment
Reveals profitability across different business units, highlighting which segments drive earnings and where there may be challenges or opportunities for growth.
Reveals profitability across different business units, highlighting which segments drive earnings and where there may be challenges or opportunities for growth.
Data provided by:
The Fly
The FlyGinkgo Bioworks Holdings (DNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$875.42M
Dividend YieldN/A
Average Volume (3M)2.60M
Price to Earnings (P/E)―
Beta (1Y)3.09
Revenue Growth-51.54%
EPS Growth7.05%
CountryUS
Employees485
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.02
Shares Outstanding55,383,810
10 Day Avg. Volume4,923,160
30 Day Avg. Volume2,596,563
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue6.39
Enterprise Value/Gross Profit7.97
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
$7.00Price Target Upside-7.16% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-3.5
Revenue Forecast (FY)$85.03M
Ginkgo Bioworks Holdings Business Overview & Revenue Model
Company Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and deve...
How the Company Makes Money
Ginkgo primarily makes money by providing cell engineering and related synthetic biology services to partners and customers, typically structured as (1) upfront and ongoing R&D/service revenue for performing organism design, strain engineering, te...
Ginkgo Bioworks Holdings Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The call balanced significant strategic and operational progress with near-term financial headwinds. Positives include major academic and national lab contracts, rapid expansion and scale demonstration of Nebula, a competitive ADME product with strong price/performance and a solid cash position plus a reduced long‑term Google Cloud commitment. Negatives include steep year‑over‑year revenue declines, wider GAAP losses and worse adjusted EBITDA in Q2, elevated quarter‑specific cash burn and ongoing excess lease costs. Management emphasizes cost discipline, a shift toward investing in autonomous labs and predictable cash burn guidance for 2026, but revenue recognition timing for automation deals and the need to further mature operations create near‑term uncertainty.Positive Updates
Strategic NSF and Academic Wins
Selected to build autonomous labs for MIT, Caltech, University of Maryland and Northwestern (NSF-funded or separate grant for MIT), positioning Ginkgo as a supplier of campus cloud/autonomous labs and training the next generation of scientists.
Negative Updates
Sharp Revenue Decline
Q2 2026 revenue was $20M, down 48% YoY; revenue for the first 6 months of 2026 was $40M, down 49% YoY (or ~42% decline excluding $7.5M noncash revenue in H1 2025 related to BiomEdit).
Read all updates
Q2-2026 Updates
Positive
Negative
Strategic NSF and Academic Wins
Selected to build autonomous labs for MIT, Caltech, University of Maryland and Northwestern (NSF-funded or separate grant for MIT), positioning Ginkgo as a supplier of campus cloud/autonomous labs and training the next generation of scientists.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 cash‑burn guidance of $125 million to $150 million while saying they expect further cash‑burn improvement in H2; the company enters H2 with $302 million of cash and cash equivalents plus $87 million of restricted cash. Key Q2 and H1 metrics cited: Q2 revenue $20 million (down 48% YoY) and H1 revenue $40 million (down 49% YoY; ~42% decline ex. $7.5 million non‑cash BiomEdit item), R&D $30 million in Q2 (down 4% YoY), G&A $12 million in Q2 (down 26% YoY), net loss from continuing operations of $57 million in Q2 (vs $53 million prior year), and adjusted EBITDA of negative $36 million in Q2 (vs negative $25 million), which includes $14 million of excess‑lease carrying costs (up from $12 million). Cash‑burn was $45 million in Q2 and $93 million in the first half (down 3% from $96 million), noting a $17 million ATM raise (excluded from cash‑burn) and a $14 million Google Cloud payment in Q1 that raised near‑term burn; the Google Cloud reset reduced future minimum commitments by more than $100 million and extended the term from 3 to 6 years.Ginkgo Bioworks Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 111.86M | 170.16M | 227.04M | 251.46M | 477.71M | 313.84M |
| Gross Profit | 89.59M | 138.63M | 188.49M | 197.45M | 273.49M | 184.15M |
| EBITDA | -242.01M | -254.61M | -484.39M | -821.29M | -2.08B | -1.81B |
| Net Income | -290.80M | -312.76M | -547.03M | -892.87M | -2.10B | -1.83B |
Balance Sheet | ||||||
| Total Assets | 990.05M | 1.12B | 1.38B | 1.67B | 2.54B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 302.16M | 422.62M | 561.57M | 944.07M | 1.32B | 1.55B |
| Total Debt | 404.11M | 439.88M | 467.73M | 239.31M | 442.59M | 23.03M |
| Total Liabilities | 569.76M | 611.11M | 661.39M | 568.19M | 803.04M | 503.61M |
| Stockholders Equity | 420.28M | 508.59M | 716.06M | 1.10B | 1.74B | 1.51B |
Cash Flow | ||||||
| Free Cash Flow | -190.12M | -178.72M | -382.13M | -336.30M | -304.47M | -310.34M |
| Operating Cash Flow | -170.24M | -171.06M | -319.58M | -295.50M | -252.20M | -253.82M |
| Investing Cash Flow | 56.50M | -240.29M | -62.24M | -80.69M | -67.39M | -73.26M |
| Financing Cash Flow | 34.55M | 17.77M | -1.74M | -3.22M | 95.34M | 1.53B |
Ginkgo Bioworks Holdings Technical Analysis
Positive
7.54
Price Trends
8.58
Positive
8.64
Positive
8.43
Positive
Market Momentum
1.33
Negative
63.02
Neutral
23.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNA, the sentiment is Positive. The current price of 7.54 is below the 20-day moving average (MA) of 10.35, below the 50-day MA of 8.58, and below the 200-day MA of 8.43, indicating a bullish trend. The MACD of 1.33 indicates Negative momentum. The RSI at 63.02 is Neutral, neither overbought nor oversold. The STOCH value of 23.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNA.
Ginkgo Bioworks Holdings Risk Analysis
Ginkgo Bioworks Holdings disclosed 69 risk factors in its most recent earnings report. Ginkgo Bioworks Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ginkgo Bioworks Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $212.85M | 13.78 | 20.50% | ― | 10.99% | -12.12% | |
59 Neutral | $1.74B | -12.79 | -59.21% | ― | -62.28% | 15.36% | |
55 Neutral | $875.42M | -2.59 | -60.21% | ― | -51.54% | 7.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $529.99M | -34.62 | -13.08% | ― | ― | 29.73% | |
45 Neutral | $915.17M | -5.24 | -49.11% | 23.67% | ― | 91.41% | |
43 Neutral | $213.44M | -0.54 | -91.62% | ― | -55.00% | 51.58% |
* Healthcare Sector Average
DNA
Ginkgo Bioworks Holdings
13.00
-0.16
-1.22%
NAGE
Niagen Bioscience
2.69
-4.77
-63.94%
MNPR
Monopar Therapeutics Inc
78.96
-23.09
-22.63%
LYEL
Lyell Immunopharma
8.71
-8.12
-48.25%
JBIO
Jade Biosciences
14.39
5.30
58.31%
ABSI
AbSci
10.16
6.50
177.60%
Ginkgo Bioworks Holdings Corporate Events
Business Operations and StrategyFinancial Disclosures
Ginkgo Bioworks to Review Q2 2026 Performance
Neutral
Jul 30, 2026
Ginkgo Bioworks Holdings, Inc., a synthetic biology tools provider offering autonomous, robotics-powered labs and cloud-based contract research services, focuses on making biological engineering more accessible and productive for scientists and co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.